Safrole Suppresses Murine Myelomonocytic Leukemia WEHI-3 Cells In Vivo, and Stimulates Macrophage Phagocytosis and Natural Killer Cell Cytotoxicity in Leukemic Mice

Fu-Shun Yu,1 Jai-Sing Yang,2 Chun-Shu Yu,3 Jo-Hua Chiang,4 Chi-Cheng Lu,4 Hsiung-Kwang Chung,5,6 Chien-Chih Yu,3 Chih-Chung Wu,7 Heng-Chien Ho,8* Jing-Gung Chung9,10*

1Department of Dental Hygiene, China Medical University, Taichung 404, Taiwan
2Department of Pharmacology, China Medical University, Taichung 404, Taiwan
3School of Pharmacy, China Medical University, Taichung 404, Taiwan
4Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan
5Graduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan
6Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404, Taiwan
7Department of Nutrition and Health Sciences, Chang Jung Christian University, Tainan 711, Taiwan
8Department of Biochemistry, China Medical University, Taichung 404, Taiwan
9Department of Biological Science and Technology, China Medical University, Taichung 404, Taiwan
10Department of Biotechnology, Asia University, Taichung 413, Taiwan

ABSTRACT: Many anticancer drugs are obtained from phytochemicals and natural products. However, some phytochemicals have mutagenic effects. Safrole, a component of Piper betle inflorescence, has been reported to be a carcinogen. We have previously reported that safrole induced apoptosis in human oral cancer cells in vitro and inhibited the human oral tumor xenograft growth in vivo. Until now, there is no information addressing if safrole promotes immune responses in vivo. To evaluate whether safrole modulated immune function, BALB/c mice were intraperitoneally injected with murine myelomonocytic WEHI-3 leukemia cells to establish leukemia and then were treated with or without safrole at 4 and 16 mg/kg. Animals were sacrificed after 2 weeks post-treatment with safrole for examining the immune cell populations, phagocytosis of macrophages and the natural killer (NK) cells’ cytotoxicity. Results indicated that safrole...
increased the body weight, and decreased the weights of spleen and liver in leukemic mice. Furthermore, safrole promoted the activities of macrophages phagocytosis and NK cells’ cytotoxicity in leukemic mice when compared with untreated leukemic mice. After determining the cell marker population, we found that safrole promoted the levels of CD3 (T cells), CD19 (B cells) and Mac-3 (macrophages), but it did not affect CD11b (monocytes) in leukemic mice. In conclusion, safrole altered the immune modulation and inhibited the leukemia WEHI-3 cells in vivo.

INTRODUCTION

It is well documented that diet can play a vital role in cancer prevention (Chen and Xu, 2010). Increased consumption of a plant-based diet may reduce the risk of cancer development from epidemiological and animal studies (Mahmoud et al., 2000; Mutoh et al., 2000; Wenzel et al., 2000; Chiang et al., 2011). Leukemia is one of cancer-related cause death worldwide. About 3.7 individuals per 100,000 die each year from leukemia in the United States (Jensen et al., 2004). Based on a 2009 report of the Department of Health, Executive Yuan, Taiwan, about 4/100,000 individuals die of leukemia in Taiwan (Lin et al., 2011). At present, there is going attention to discover chemotherapy for leukemia, and it is vital for treatment approach.

In Taiwan, it was reported that people chewing betel quid containing Piper betle inflorescence or leaf, an Asian climbing tropical plant (Piperaceae family), induced high concentration of safrole (420 \mu M) in the saliva to increase the risk of oral caner (Wang and Hwang, 1993; Chen et al., 1999). Although safrole has been recognized to be as a group 2B carcinogen, there are no adequate evidences elucidating the relationship between exposure to safrole and human cancers (IARC, 1976). Safrole has been reported to cause marked \([Ca^{2+}]\) elevation and decrease cell viability in human osteosarcoma cells (Lin et al., 2006), and binds to DNA forming safrole-DNA adducts (Daimon et al., 1997, 1998; Lee et al., 2005).

It was reported that safrole reduced the bactericidal activity of polymorphonuclear leukocytes (PMNs) against Actinobacillus actinomycetemcomitans and it also decreased the release of superoxide anions from PMNs (Hung et al., 2003). Our previous studies have shown that safrole induced apoptosis in human oral cancer HSC-3 cells in vitro and reduced xenograft mice model in vivo (Yu et al., 2011b). Also, safrole induced apoptotic death in human tongue squamous cancer SCC-4 cells via mitochondria-dependent caspases activation signaling (Yu et al., 2011a). Currently, there is no report showing the effects of safrole on the function of immune system of leukemic mice in vivo. This study investigated that safrole might promote phagocytosis of macrophages and increase cytotoxicity of natural killer (NK) cells from leukemic BALB/c mice in vivo.

MATERIALS AND METHODS

Materials and Reagents

Safrole, dimethyl sulfoxide (DMSO), and propidium iodide (PI) were obtained from Sigma-Aldrich Corp. (St. Louis, MO). RPMI-1640 medium, fetal bovine serum (FBS), penicillin-streptomycin and L-glutamine were obtained from Invitrogen Life Technologies (Carlsbad, CA).

Murine WEHI-3 Leukemia Cell Line

The WEHI-3 murine myelomonocytic leukemia cell line was obtained from the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cells were cultured in culture plastic flasks (75-cm²) at 37 °C under a humidified 5% CO₂ atmosphere in RPMI-1640 medium supplemented with 10% FBS, 2 mML-glutamine, 100 units/mL penicillin, and 100 \mu g/mL streptomycin. The cells were cultivated for two complete cycles in an incubator.

Male BALB/c Mice

Fifty male BALB/c mice 6 weeks of age and 22–28 g in weight were obtained from the Laboratory Animal Center, College of Medicine, National Taiwan University (Taipei, Taiwan). Animals for this study were used according to the institutional guidelines (Affidavit of Approval of Animal Use Protocol, No. 96-147-C) approved by the Institutional Animal Care and Use Committee (IACUC) of China Medical University (Taichung, Taiwan).

Establish Leukemic Mice and Safrole Treatment

Fifty BALB/c mice were randomly divided into 5 groups to receive different treatments. Three groups of 10 mice per group were intraperitoneally (i.p.) injected with 1 \times 10^5 WEHI-3 cells per mouse and maintained for 2 weeks to generate the leukemic mice model (Glass et al., 1996; Yang et al., 2006). Thereafter, these mice were randomly distributed into 3 different groups receiving vehicle only (olive oil) and safrole (4 and 16 mg/kg) (Yu et al., 2011b). The other twenty normal mice served as the control (10
animals) or were treated with vehicle (olive oil; 10 animals), respectively. Safrole was administered by oral gavage to treating the groups by the above doses daily for up to 2 weeks before being weighed and sacrificed.

Weights of Body, Spleen, and Liver Tissues

All animals were weighed and blood was withdrawn. Spleen and liver samples were isolated and weighed individually (Tsou et al., 2009; Lin et al., 2010).

Phagocytic Activity of Macrophages

PHAGOTEST kit (Glycotope Biotechnology GmbH, Heidelberg, Germany) was used to measure the phagocytosis as previously described (Lin et al., 2010; Yu et al., 2010). At the end of treatment, heparinized blood samples of 1 mL from all experimental mice were collected before animals were sacrificed. Peritoneal macrophages from each mouse in saffrole-treated or untreated groups were isolated as described elsewhere (Hendriks et al., 2008), $1 \times 10^5$ leukocytes in 100 µL of whole blood and peritoneal cavity from each treatment of all groups were incubated for 1 h at 37°C with fluorescein isothiocyanate (FITC)-labeled opsonized Escherichia coli (E. coli) ($2 \times 10^7$ bacteria in 20 µL 1X solution from the kit). The quenching solution (100 µL) was added to the reaction and then the whole blood is lysed and fixed with 2 mL of 1X lysing solution for 20 min at room temperature according to the manufacturer’s instruction. After the completion of phagocytosis by macrophages, DNA was stained according to the manufacturer’s protocol. Cells from each sample were analyzed by flow cytometry (Becton Dickinson, FACSCalibur™, Franklin Lakes, NJ) as previously described (Lin et al., 2010). Fluorescence data were collected on 10,000 cells and analyzed using the BD CELLQUEST Pro software.

Whole Blood Samples and Immunofluorescence Staining for Surface Markers

The blood samples of 500 µL from each group were individually exposed to 1X Pharm Lyse™ lysing buffer (BD Biosciences, San Jose, CA) for lysing of the red blood cells. Subsequently, all samples were centrifuged for 15 min at $350 \times g$ at 4°C and washed with phosphate buffer saline (PBS). The isolated white blood cells from each treatment were stained by the FITC-conjugated antimouse CD3, phycoerythrin (PE)-conjugated antimouse CD19, PE-conjugated antimouse Mac-3 and FITC-conjugated antimouse CD11b antibodies (BD Pharmingen Inc, San Diego, CA) before being analyzed to determine the levels of cell markers by flow cytometry as previously described (Lin et al., 2010; Yu et al., 2010).

Fig. 1. Safrole affected the body, spleen, and liver weights of leukemic BALB/c mice. The animals were intraperitoneally injected with WEHI-3 cells ($1 \times 10^6$ cells/100 µL per mouse) for 2 weeks and then orally treated with or without saffrole (4 and 16 mg/kg/mice) for 2 weeks. The body (A), spleen (B), and liver (C) weights were weighted as described in the “Materials and Methods” Section. Each point is mean ± S.D ($n = 10$). *$p < 0.05$ was considered significant when compared with the WEHI-3 leukemic mice.
NK Cell Cytotoxicity

At the end of treatment, the fresh spleens from all experimental mice were processed to isolate splenocytes (Chang et al., 2009; Lin et al., 2010). About $1 \times 10^5$ splenocytes in 1 mL RPMI-1640 medium were cultured in each well of 24-well culture plates. About $1 \times 10^6$ of YAC-1 cells were cultured in 15 mL tubes with serum-free RPMI-1640 medium and then PKH-67/Diluent C buffer (Sigma-Aldrich Corp.) was added to the cells, mixed thoroughly for 2 min at 25°C then 2 mL PBS was added for 1 min. RPMI-1640 medium at 4 mL was added for a 10 min-incubation then were followed by centrifugation at 350×g of 25°C. YAC-1 cells in 100 μL were placed on 96-well plates before the addition of the leukocytes from each treatment to the wells for 12 h and determination of NK cell cytotoxic activity by a PI exclusion assay and flow cytometry as previously described (Chang et al., 2009; Lin et al., 2010; Lu et al., 2010).

Statistical Analysis

The results were expressed as mean ± S.D. and the difference between control and safrole-treated groups was analyzed by one-way the analysis of variance (one-way ANOVA) followed by Dunnett’s test. A $p$-value of less than 0.05 was taken as significant.

RESULTS

Safrole Affected the Body, Spleen, and Liver Weights in WEHI-3 Leukemic BLAB/c Mice

At the end of safrole treatment, body weights of each animal were weighed then spleen or liver tissues were isolated and were weighed. Safrole increased the body weights of each treatment as compared with the leukemic mice group.
Fig. 3. Safrole affected the levels of cell markers in white blood cells from BALB/c leukemic mice. The animals were intraperitoneally injected with WEHI-3 cells \((1 \times 10^5\) cells/mouse) for 2 weeks and orally treated with or without safrole for 2 weeks. Blood was collected from each group of animal and analyzed for cell surface markers by flow cytometry as described in the “Materials and Methods” Section. The profiles from flow cytometric analysis by using BD CELLQUEST Pro software were shown the levels of CD3 (X-axis) and CD19 (Y-axis) double staining (A), CD11b (B) as well as Mac-3 (C). The data are expressed the similar results at least three experiments. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Safrole Promoted the Phagocytosis by Macrophages from Peripheral Blood Mononuclear Cells (PBMC) and Peritoneal Cavity in WEHI-3 Leukemia BALB/c Mice

To investigate whether or not safrole affected phagocytosis, the leukocytes from safrole-treated or untreated groups were isolated and phagocytic activity was measured. Safrole (4 and 16 mg/kg/day) promoted the activity of phagocytosis from PBMC (4 mg/kg/day: 16.4%; 16 mg/kg/day: 6.0%) [Fig. 2(A,B)] and peritoneal cavity (4 mg/kg/day: 6.5%; 16 mg/kg/day: 12.1%) [Fig. 2(C,D)] from leukemic mice by comparison to control (untreated leukemic mice).

Safrole Altered the Surface Markers of Whole Blood Cells from WEHI-3 Leukemic BALB/c Mice

To investigate whether safrole affected the levels of cell surface marker, leukocytes from normal and leukemic mice in the absence and presence of safrole exposure were isolated and levels of CD3, CD19, Mac-3, and CD11b were determined by flow cytometric analysis. Safrole increased the levels of CD3 [Fig. 3(A) and Table I] (4 mg/kg/day: 5.3%), CD19 [Fig. 3(A) and Table I] (4 mg/kg/day: 5.9%) and Mac-3 [Fig. 3(C) and Table I] (4 mg/kg/day: 3.6%; 16 mg/kg/day: 3.8%), but it did not significantly affect the level \( p > 0.05 \) of CD11b [Fig. 3(D) and Table I] when compared with the leukemic group without safrole treatment.

Safrole Affected NK Cell Cytotoxic Activity of Splenocytes from WEHI-3 Leukemia BALB/c Mice

To determine whether safrole affects NK cell cytotoxicity, splenocytes from safrole-treated or untreated groups were isolated and NK cell cytotoxicity was determined by flow cytometry. YAC-1 target cells were killed by NK cells derived exclusively from the higher dose of safrole tested (16 mg/kg/day) compared to the untreated control leukemic mice. Safrole at the higher dose tested (16 mg/kg/day) was effective at both target ratios of 50/1 and 25/1 as shown in Figure 4.

### Table I. Effects of cell surface markers of white blood cells from normal and leukemic BALB/c mice

<table>
<thead>
<tr>
<th>Groups</th>
<th>CD3(^+) (%)</th>
<th>CD19(^+) (%)</th>
<th>CD11b(^+) (%)</th>
<th>Mac-3(^+) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>35.95 ± 1.75</td>
<td>26.43 ± 0.92</td>
<td>30.80 ± 0.54</td>
<td>1.03 ± 0.20</td>
</tr>
<tr>
<td>Olive oil</td>
<td>36.02 ± 1.91</td>
<td>25.50 ± 1.91</td>
<td>31.23 ± 1.51</td>
<td>1.17 ± 0.31</td>
</tr>
<tr>
<td>WEHI-3</td>
<td>15.70 ± 0.49</td>
<td>12.74 ± 1.56</td>
<td>54.80 ± 1.50</td>
<td>2.85 ± 0.13</td>
</tr>
<tr>
<td>WEHI-3/Safrole 4 mg/kg</td>
<td>20.61 ± 0.42*</td>
<td>18.44 ± 0.25*</td>
<td>54.02 ± 2.03</td>
<td>5.88 ± 0.65*</td>
</tr>
<tr>
<td>WEHI-3/Safrole 16 mg/kg</td>
<td>17.78 ± 0.58</td>
<td>13.25 ± 0.22</td>
<td>56.31 ± 0.63</td>
<td>6.15 ± 0.56*</td>
</tr>
</tbody>
</table>

Results show significant differences between values for WEHI-3 leukemic mice and safrole treatment groups. Mice after intraperitoneal injection with WEHI-3 cells \((1 \times 10^5 \text{cells/mouse})\) for 2 weeks were exposed to safrole (4 and 16 mg/kg) for 2 weeks by oral administration. Thereafter, leukocytes in heparinized whole blood from each group of mice were stained with FITC anti-mouse CD3, PE anti-mouse CD19, PE anti-mouse Mac-3, and FITC anti-mouse CD11b antibodies, respectively, for determining cell surface markers by using flow cytometric analysis as described in the “Materials and Methods” Section.

An asterisk (*) is considered significant \((p < 0.05)\) by one-way ANOVA followed by Dunnett’s test and all data were expressed as the mean ± S.D. \((n = 10)\).
**DISCUSSION**

Several reports demonstrate that safrole acts as a carcinogen and it can bind to DNA of cells (Daimon et al., 1997, 1998; Chen et al., 1999; Lin et al., 2006). It was also reported that safrole decreased cell viability and cause marked [Ca$^{2+}$] elevation in human osteosarcoma cells (Lin et al., 2006). Recently, we demonstrated that safrole induced cytotoxic effects and induction of apoptosis in human oral cancer cells *in vitro* (Yu et al., 2011a,b) and xenograft animal model *in vivo* (Yu et al., 2011b). In this study, we aimed to address the effect of safrole on immune responses in leukemic mice *in vivo*. Herein, we established leukemic BALB/c mice through the intraperitoneal injection with murine WEHI-3 cells (Yang et al., 2006; Lu et al., 2007), and then chronically treated mice with safrole. Our findings suggest that safrole promoted the phagocytosis by macrophages [Fig. 2(A,C)] and elevated the cytotoxicity of NK cells (Fig. 4). Thus, safrole could not only increase the humoral immune response (B cells and promoted macrophage activities), but also the cellular immune response (T lymphocytes) when the leukemic mice were treated with safrole [Fig. 3(A) and Table I]. Safrole significantly enhanced NK cell cytotoxic activity (Fig. 4) in leukemic mice. It is well known that both of macrophage phagocytosis and NK cell cytotoxicity play major roles for immune responses after animals were exposed to antigen human T cell and monocyte modulating activity of *Rhizoma typhonii* *in vitro* (Thomas et al., 1985; Shan et al., 2001; Mulligan et al., 2008). These findings suggest that safrole might increase the immune response and promote the activities of macrophage and NK cells against leukemia in general. Therefore, safrole is itself a suspected carcinogen and was found to induce the formations of DNA adducts (Daimon et al., 1998; Chen et al., 1999). However, our study supports important information regarding that lower dose (less than 16 mg/kg) of safrole might affect the immune modulation and suppress the leukemia WEHI-3 cells *in vivo*.

Many reports have stated that T-lymphocytes presented CD3 antigen on cell surface membranes are involved in cell-mediated immunity in cellular immunomodulatory system, and B cells are primarily mediated in humoral immunity (Krop et al., 1996; Mitsuzumi et al., 1998; Lu et al., 2011). Hence, we also examined the cell markers from PBMC of leukemic mice after oral treatment of safrole and our results indicated that the percentages of CD3 (T cells), CD19 (B cells) and Mac-3 (macrophages) were significantly increased in safrole-treated leukemic mice, but that the population of CD11b (monocytes) were not significantly affected in leukemic mice after safrole exposure (Fig. 3 and Table I). It is reported that nonactivated B cells are shown CD19 marker and their differentiation modulate by the interaction of various types of cytokines secreted from macrophages or T cells (Mitsuzumi et al., 1998). Our results showed that safrole could increase B cells (elevated the population of CD19), and the augmenting effect of safrole is carried out through the antibody responses resulted from expansion and differentiation of mainly monocytes and macrophages.

In conclusions, this study suggests that safrole reduces leukemia-related splenomegaly and spleen growth in leukemic mice. Safrole promotes immune responses in BALB/c leukemic mice *in vivo*. Safrole acts as a potent immunological adjuvant *in vivo* and its application provides an effective strategy to improve the efficacy of immune responses. However, the antileukemia effects on molecular mechanisms of safoel-treated *in vitro* and *in vivo* studies are not well done, and the further investigations are, therefore, necessary for this study.

**REFERENCES**


